Logo

Indications - In Chronic Spasticity: Dantrolene is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g. spinal cord injury, stroke, cerebral palsy, multiple sclerosis etc.). Dantrolene is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.

Dosage & Administration - For Use in treatment of Chronic Spasticity: Adults: Initial dose: 25 mg once daily for seven days. Maintenance dose: 25-50 mg thrice daily for seven days. Maximum daily dose: 100 mg orally 4 times daily. Pediatric Patients: Initial dose: 0.5 mg/kg once daily for seven days. Maintenance dose: 0.5-1 mg/kg thrice daily for seven days.

Side Effects - The most frequently occurring side effects of Dantrolene have been drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea. These are generally transient, occurring early in treatment, and can often be obviated by beginning with a low dose and increasing dosage gradually until an optimal regimen is established. Diarrhea may be severe and may necessitate temporary withdrawal of Dantrolene therapy. If diarrhea recurs upon readministration of Dantrolene, therapy should probably be withdrawn permanently

Contraindications - Active hepatic disease, such as hepatitis and cirrhosis.

Others - Pregnancy & Lactation Pregnancy Category C. Dantrolene capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Dantrolene should not be used in nursing mothers.